SCHEMBL5044320

SCHEMBL5044320

COc1ccc(-c2nc(-c3cc(C(=O)O)c(C)n3CC3CCCO3)cs2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.67
CDC25B P30305 1/20 0.67
CDC25C P30307 1/20 0.67
DUSP3 P51452 1/20 0.67
ALDH1A1 P00352 16/20 0.49
KDM4E B2RXH2 6/20 0.49
GAA P10253 3/20 0.49
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
USP2 O75604 5/20 0.46
HTT P42858 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 7/20 0.46
GLA P06280 1/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043937 0.88 CDC25A (0.59) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5039512 0.88 CDC25A (0.61) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5039301 0.87 CDC25A (0.49) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5048712 0.87 CDC25A (0.59) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5046853 0.87 CDC25A (0.59) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5044586 0.87 CDC25A (0.59) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5043698 0.87 CDC25A (0.50) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5039354 0.86 CDC25A (0.49) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL6871888 0.83 CDC25A (0.46) CDC25ACDC25BCDC25CDUSP3ALDH1A1
SCHEMBL5039472 0.83 CDC25A (0.46) CDC25ACDC25BCDC25CDUSP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R CDC25A 1091/4885CDC25B 1444/4885CDC25C 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.